Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assay.

Kennedy R, Pankratz VS, Swanson E, Watson D, Golding H, Poland GA.

Clin Vaccine Immunol. 2009 Aug;16(8):1105-12. doi: 10.1128/CVI.00109-09. Epub 2009 Jun 17.

2.

A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China.

Liu Q, Huang W, Nie J, Zhu R, Gao D, Song A, Meng S, Xu X, Wang Y.

PLoS One. 2012;7(3):e33392. doi: 10.1371/journal.pone.0033392. Epub 2012 Mar 16.

3.

Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.

Hughes CM, Newman FK, Davidson WB, Olson VA, Smith SK, Holman RC, Yan L, Frey SE, Belshe RB, Karem KL, Damon IK.

Clin Vaccine Immunol. 2012 Jul;19(7):1116-8. doi: 10.1128/CVI.00056-12. Epub 2012 May 16.

4.

Development of a novel vaccinia-neutralization assay based on reporter-gene expression.

Manischewitz J, King LR, Bleckwenn NA, Shiloach J, Taffs R, Merchlinsky M, Eller N, Mikolajczyk MG, Clanton DJ, Monath T, Weltzin RA, Scott DE, Golding H.

J Infect Dis. 2003 Aug 1;188(3):440-8. Epub 2003 Jul 16.

PMID:
12870127
5.

Monitoring of human immunological responses to vaccinia virus.

Harrop R, Ryan MG, Golding H, Redchenko I, Carroll MW.

Methods Mol Biol. 2004;269:243-66. Review.

PMID:
15114020
6.

A rapid, high-throughput vaccinia virus neutralization assay for testing smallpox vaccine efficacy based on detection of green fluorescent protein.

Johnson MC, Damon IK, Karem KL.

J Virol Methods. 2008 Jun;150(1-2):14-20. doi: 10.1016/j.jviromet.2008.02.009. Epub 2008 Apr 2.

PMID:
18387679
7.

Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus.

Cosma A, Bühler S, Nagaraj R, Staib C, Hammarin AL, Wahren B, Goebel FD, Erfle V, Sutter G.

Clin Diagn Lab Immunol. 2004 Mar;11(2):406-10.

8.

Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.

Grosenbach DW, Jordan R, King DS, Berhanu A, Warren TK, Kirkwood-Watts DL, Tyavanagimatt S, Tan Y, Wilson RL, Jones KF, Hruby DE.

Vaccine. 2008 Feb 13;26(7):933-46. doi: 10.1016/j.vaccine.2007.11.095. Epub 2007 Dec 26.

9.

Accuracy and repeatability of a micro plaque reduction neutralization test for vaccinia antibodies.

Borges MB, Kato SE, Damaso CR, Moussatché N, da Silva Freire M, Lambert Passos SR, do Nascimento JP.

Biologicals. 2008 Mar;36(2):105-10. Epub 2007 Sep 24.

PMID:
17892944
10.

Evaluation of smallpox vaccines using variola neutralization.

Damon IK, Davidson WB, Hughes CM, Olson VA, Smith SK, Holman RC, Frey SE, Newman F, Belshe RB, Yan L, Karem K.

J Gen Virol. 2009 Aug;90(Pt 8):1962-6. doi: 10.1099/vir.0.010553-0. Epub 2009 Apr 1.

11.

Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations.

Hatakeyama S, Moriya K, Saijo M, Morisawa Y, Kurane I, Koike K, Kimura S, Morikawa S.

Clin Diagn Lab Immunol. 2005 Apr;12(4):520-4.

12.

Gender effects on humoral immune responses to smallpox vaccine.

Kennedy RB, Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Ryan MA, Poland GA.

Vaccine. 2009 May 26;27(25-26):3319-23. doi: 10.1016/j.vaccine.2009.01.086. Epub 2009 Feb 5.

13.

Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens.

Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S.

Virology. 2008 Feb 5;371(1):98-107. Epub 2007 Oct 24.

14.

Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults.

Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, Monath TP.

Vaccine. 2009 Mar 4;27(10):1637-44. doi: 10.1016/j.vaccine.2008.11.079. Epub 2008 Dec 9.

PMID:
19071184
15.

Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine.

Benhnia MR, McCausland MM, Su HP, Singh K, Hoffmann J, Davies DH, Felgner PL, Head S, Sette A, Garboczi DN, Crotty S.

J Virol. 2008 Apr;82(7):3751-68. doi: 10.1128/JVI.02244-07. Epub 2008 Jan 30.

16.

Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.

J Virol. 2008 Apr;82(7):3517-29. doi: 10.1128/JVI.01854-07. Epub 2008 Jan 16.

17.

Correlations between vaccinia-specific immune responses within a cohort of armed forces members.

Umlauf BJ, Ovsyannikova IG, Haralambieva IH, Kennedy RB, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA.

Viral Immunol. 2011 Oct;24(5):415-20. doi: 10.1089/vim.2011.0029. Epub 2011 Sep 29.

18.
19.
20.

Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.

He Y, Manischewitz J, Meseda CA, Merchlinsky M, Vassell RA, Sirota L, Berkower I, Golding H, Weiss CD.

J Infect Dis. 2007 Oct 1;196(7):1026-32. Epub 2007 Aug 20.

PMID:
17763325

Supplemental Content

Support Center